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Abstract 
Introduction: Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is a non-invasive 
imaging modality that has been shown to be a feasible method to demonstrate myocardial 
inflammation. The aim of this study was to identify the patients suspected of having cardiac 
sarcoidosis (CS), who are most likely to benefit from PET imaging. 
Materials and methods: 137 patients suspected of having CS underwent a dedicated cardiac FDG-
PET examination at Tampere University Hospital between August 2012 and September 2015. 
These examinations were retrospectively analysed.   
Results: 33 and 12 of the 137 patients had abnormal left and right ventricular (LV and RV) FDG 
uptake respectively. Abnormal LV-uptake and RV-uptake were significantly associated with female 
sex and a history of advanced AV-block (p < 0.05). Abnormal RV uptake was also associated with 
ventricular tachycardia and atrial fibrillation (p < 0.05).  56% of the 27 female patients with a 
history of AV-block had a pathological PET finding compared to only 6% of the 49 male patients 
without a history of AV-block. There were 17 female patients with history of both AV-block and 
ventricular tachycardia, 71% of them had abnormal PET finding. 
Conclusions: Abnormal FDG-PET findings were associated with female sex, AV-block and 
arrhythmias in this clinical cohort. 
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Abbreviations: CS=cardiac sarcoidosis; EMB=endomyocardial biopsy; FDG-PET= 
¹⁸Fluorodeoxyglucose positron emission tomography; RV= right ventricle; LV= left ventricle; 
AV=atrio-ventricular; VT= ventricular tachycardia, MPI= myocardial perfusion imaging 
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Introduction 
  
Sarcoidosis is a multisystem granulomatous inflammatory disorder that can affect any organ 
system. The disease most commonly manifests in the lungs, typically as an asymptomatic hilar 
lymph node enlargement. The incidence of sarcoidosis differs between populations according to 
their genetic background (1). In Europe, Scandinavians have the highest prevalence (2). At autopsy, 
27% of sarcoidosis patients showed cardiac involvement, which is the most frequent cause of 
sarcoidosis-related death (3, 4, 5, 6). In 40-50% of patients, cardiac sarcoidosis (CS) is diagnosed 
pre-mortem (7). Due to the difficulty of diagnosing CS, epidemiological literature on the topic is 
sparse. In Finland, the prevalence of biopsy-confirmed CS is 2.2/100.000. In 65% of such cases, 
sarcoidosis is confined to the heart without clinical manifestations in other organs. The true 
incidence of CS is probably higher because all clinically diagnosed cases without biopsy 
verification were excluded (8).  
According to the guidelines issued in 2006 by the Japanese Ministry of Health and Welfare 
(JMHW) and revised by the Japan Society of Sarcoidosis and Other Granulomatous Disorders, CS 
can be diagnosed directly by verifying cardiac involvement on biopsy or indirectly via 
histologically proven extra-cardiac sarcoidosis combined with electrocardiographic and imaging 
findings (9). The revised criteria were proposed by the Heart Rhythm Society in 2014 (10). 
According to both guidelines, CS can only be diagnosed if there is direct proof by endomyocardial 
biopsy (EMB) or previously diagnosed systemic sarcoidosis combined with clinical and imaging 
findings indicating cardiac involvement. Given that the sensitivity of EMB is low, a large share of 
patients with probable CS does not fulfil the current diagnostic criteria (11). Thus, imaging is also 
needed in the diagnostic workup for CS. Criteria for diagnosing isolated CS relying partly on 
imaging were proposed by Isobe in 2015 (12).  
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Cardiac 18fluorodeoxyglucose positron emission tomography/computerized tomography (18FDG 
PET/CT) (later referred to as PET) has been used to identify active cardiac inflammation, with a 
sensitivity and specificity of 89% and 78%, respectively (13). PET is not included in the JMHW 
guidelines. The demand for cardiac imaging has increased because it has been suggested that CS 
should be excluded in patients under the age of 55 with unexplained dilated cardiomyopathy, II or 
III degree atrioventricular (AV-) block or persistent ventricular tachycardia (VT) (10, 11). The aim 
of the present study was to evaluate the use of PET in the diagnostic workup of patients with 
symptoms suggestive of CS in a clinical setting. Because PET imaging is relatively expensive and 
involves radiation, it is clinically relevant to identify the patients who are most likely to benefit 
from the diagnostic method and to recognize the factors that predict a diagnosis of CS. 
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Materials and methods  
Study population 
We retrospectively screened all cardiac PET studies performed in the Tampere University Hospital 
from August 2012 to September 2015. We excluded PET studies if clinical indication was not CS 
suspicion, where the patient’s clinical data could not be obtained or if the PET study was performed 
to follow up on previously diagnosed CS. Imaging studies were also excluded if the dedicated 
imaging protocol, as described below, was not followed precisely. Altogether 137 PET 
examinations were analysed for the present study. It is routine in our hospital to perform PET in the 
diagnostic workup of possible CS. The reason for a clinical suspicion of CS was one or more of the 
following: unexplained AV-block (n=61), ventricular (n=39) or supraventricular (n=13) arrhythmia, 
unexplained dilated cardiomyopathy (n= 27), unexplained low ejection fraction in 
echocardiography (n=46), other echocardiographic findings suggestive of CS (n=53), or syncope 
(n=27). Symptoms and clinical findings were considered unexplained by the cardiologist after 
routine studies including clinical examination, ECG and echocardiography. Coronary angiography 
was performed in case of clinical suspicion of coronary artery disease. 
 
PET Imaging 
All patients underwent an integrated PET/CT (Discovery STE 16, GE Healthcare, Milwaukee, WI, 
USA) examination. To minimize the physiological myocardial FDG uptake, the patients were 
instructed not to consume any carbohydrates during the day before the imaging and were fasting for 
12 h before the FDG injection. The patients kept a food diary during the diet. The patients were also 
instructed to avoid heavy physical exercise to minimize FDG uptake in skeletal muscle. The 
patient’s height and weight were measured before the administration of the radiopharmaceutical, 
and their blood glucose level was tested to be <7 mmol/l. The PET/CT images were acquired 
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approximately 60 min after the intravenous injection of FDG using the Medrad® Intego PET 
infusion system (Bayer Medical Care Inc., Indianola, PA, USA). The activity injected is currently 
based on the patient’s weight (3-3.2 MBq/kg). However, the protocol was changed in 2013. 
Previously, patients were given a fixed dose of 370 MBq. The mean injected activity in our study 
population was 320 MBq (range 219-460 MBq). The imaging covered a volume of two bed 
positions around the myocardium approximately from the level of shoulders to the level of the 
gallbladder. The acquisition of the images was made in the three dimensional (3D) mode with a 
128*128 matrix, 70 cm field of view (FOV) and 5 min per bed position. The PET images were 
reconstructed using the 3D VUE Point reconstruction algorithm (GE Healthcare) with 2 iterations 
and 28 subsets. Gaussian 6.0 mm FWHM was used as the post-filter. The acquisition parameters of 
the CT scanner were as follows: tube voltage, 120 kV; tube current automatic exposure control 
range, 30 – 80 mA; noise index, 33 HU; rotation speed, 35 mm/rot; and pitch, 1.75:1. The CT 
images were reconstructed to slice thicknesses of 2.50 mm, with 1.25-mm intervals. The total 
examination time for the PET/CT was approximately 15 min. CT was used for attenuation 
correction and the accurate localization of uptake. 
 
Analysis of the PET images 
We classified the uptake pattern in the left ventricular (LV) myocardium according to the 
recommendations of the Japanese Society of Nuclear Cardiology (10) as ‘none’ (no activity 
exceeding normal blood pool activity), ‘global diffuse’ (even activity over the whole myocardium) 
‘focal’ (focally increased spot(s) of activity, other regions inactive), ‘focal on diffuse’ (intense focal 
spot(s) of activity overlaid on global myocardial activity) or ‘diffuse non-global’ (faint activity on 
at least two LV walls but at least some areas of myocardium with no activity over normal blood 
pool activity). Diffuse non-global uptake is not mentioned in the Japanese Society of Nuclear 
Cardiology recommendations, but it was considered to be a similar physiological phenomenon as 
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diffuse uptake. The uptake was called physiological if it was classified as none, global diffuse or 
diffuse non-global and pathological if it was classified as focal or focal on diffuse. We also 
classified the uptake in the right ventricle (RV) in a similar manner. The maximum standardized 
uptake value (SUVmax) in the heart was measured, and its location was determined. The images 
were interpreted after patient anonymization and randomization. The images were separately 
interpreted by two experienced nuclear medicine physicians (HT, KS) blinded to all clinical data. In 
cases where the interpretation of LV uptake differed between the observers, a consensus was 
formed and used in the further analyses. 
 
Collection of clinical data 
We aimed to study the diagnostic yield of PET in relation to different patient characteristics 
(demographics, clinical history and reason for referral). The clinical data were retrospectively 
collected from the electronic medical records of Tampere University Hospital, which contains 
information from 2008 onwards. We collected demographic information, echocardiography 
findings, relevant diagnoses, symptoms and EMB findings. 
 
Statistical methods 
Statistical analyses were performed using IBM SPSS statistics version 22.0 (Armonk, NY, USA) 
and R software version 3.2.2. Chi-square and t-tests were used to compare the results. Data are 
expressed as the mean (±SD) for the continuous variables and percentages for the dichotomous 
variables. Inter-observer agreement was calculated using kappa statistics.  
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Results 
 
The inter-observer agreement in analysing the LV uptake in the PET studies was good (kappa 
0.762). The mean follow-up time (interval between PET imaging and data collection) was 692.8 
days (1 year, 10.8 months) (SD 347 days).  
104 patients had no pathological LV-uptake: 85 had no visible uptake, three had diffuse uptake and 
16 had diffuse non-global uptake pattern. Pathological LV-uptake was observed in 33 patients: 28 
had focal uptake and five had focal on diffuse uptake pattern. The mean SUVmax in the heart was 
8.5 (SD 4.1) in those with pathological uptake compared to 3.4 (SD 1.3) in those with no 
pathological uptake (p<0.001).  
Alltogether 29 (21 %) patients had focal uptake outside myocardium. Uptake foci were 
encounteded in hilar, mediastinal, axillary, subclavicular and abdominal lymph nodes, lung 
parenchyma, spleen and skeleton. 16 of the 33 patients with pathological myocardial uptake had 
pathological extracardiac foci compared to 13 of those 104 who had no pathological myocardial 
uptake (p<0.001). 
The proportions of patients with pathological PET findings according to the demographic 
information and patient history are presented in Tables 1 and 2. 13 (16 %) of the male and 20 (35 
%) of the female patients had abnormal LV uptake. Twelve patients had uptake in the RV free wall, 
ten of them were female. All patients with abnormal RV uptake also had pathological LV uptake. 
The patients with pathological PET findings were more often female and had more frequently a 
history of 2nd or 3rd degree AV-block than the patients with normal PET findings (Tables 1 and 2, 
Figure 1). Of the 137 patients 56 (41 %) had a history of 2nd or 3rd degree AV-block and 41 % of 
them had a pathological PET finding. 27 of the patients with advanced AV-block were female and 
56% of them had pathological LV-uptake. Of the 49 male patients without AV-block only 6% had 
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pathological LV-uptake. In our population, there were 75 patients with a history of VT. 31% of 
them had abnormal LV uptake and 15% had abnormal RV uptake. Abnormal RV uptake was 
significantly associated with ventricular tachycardia (Table 2). There was also a borderline 
significant (p=0.053) association between abnormal LV uptake and ventricular tachycardia (Table 
1). There was a subgroup of 17 female patients who had a history of both advanced AV-block and 
VT. 71 % of them had a pathological PET-finding. Abnormal RV uptake was also significantly 
associated with the history of atrial fibrillation (Table 2). AV-block was the only reason for referral 
significantly associated with abnormal PET findings (Tables 1 and 2). 
EBM was obtained from 21 patients. Histology was suggestive of CS in seven patients. Six of those 
had pathological LV-uptake and four also had pathological RV-uptake. However the association 
between abnormal FDG uptake and positive EMB finding was not statistically significant.  
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Discussion 
 
Few studies have dealt with the utilization of PET in the diagnostic workup of CS in a clinical 
setting. A prospective study by Yokoyama et al described the characteristics of a population of 92 
patients with a suspicion of CS (14). In that population, 40% of patients were diagnosed with CS. 
Pathological PET findings were observed in 36/37 of the patients diagnosed with CS compared with 
16/55 non-CS patients, resulting in a sensitivity of 97% and specificity of 71%. Blankstein et al (15) 
studied 118 patients with suspected CS. They found pathological LV uptake or perfusion defects in 
60% of the patients, but only 40% of those fulfilled the JMWH criteria, which resulted in low 
specificity. The authors speculated that these findings were a result of low sensitivity of the JMWH 
criteria because PET was a better predictor of future adverse events. In our population of 137 
patients, 33 had pathological LV uptake. The lower proportion of abnormal PET findings compared 
with the previously mentioned studies probably reflects our relatively unselected population; we 
included all PET studies in which there was a suspicion of CS based on patients symptoms. The 
awareness of CS as a possible cause of otherwise unexplained cardiac symptoms has resulted in an 
increased demand for cardiac PET studies at our institution during the last few years. 
AV-block was significantly associated with pathological PET findings in the present study. In our 
population, 56 patients had a history of 2nd or 3rd degree AV-block; 41% of them had pathological 
LV-uptake. Unexplained AV-block has previously been shown to indicate possible CS. In a study 
by Kandolin et al. inflammatory myocardial disease was diagnosed in 22 of 76 patients (<55 years 
old) with advanced AV-block (16).  Correlation between AV-block and FDG-uptake in the 
interventricular septum has also been reported previously (17). AV-block often causes symptoms 
resulting in referral for imaging studies in the active phase of the disease. This may in part explain 
why advanced AV-block is the most specific symptom predicting abnormal PET finding. PET 
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findings are pathological only in the active phase of myocardial inflammation but may be normal in 
the chronic fibrotic phase.  
In a previous study by Tung et al, 103 cardiomyopathy patients with ventricular arrhythmias 
underwent FDG-PET (18). In that cohort 49% of the patients had abnormal LV uptake. Nery et al. 
studied 15 patients with unexplained monomorphic VT and found that 42% had pathological LV 
uptake (19). The authors also found that CS was most often diagnosed in patients with a history of 
AV-block in combination with VT. In our population there was an association between the history 
of VT and pathological PET findings, which is in line with the previous literature. Interestingly, 
71% of the female patients with a history of both VT and AV-block had a pathological PET-finding 
in our study. 
9% of patients in the present study showed pathological uptake in the RV free wall in addition to 
pathological LV uptake. Ten of those patients were female and nine had a history of AV-block. 
Interestingly one third of patients with abnormal RV-uptake were later diagnosed with EMB-
verified CS. This percentage is rather high considering the low diagnostic yield of the EMB. In a 
study by Blankstein et al (15), pathological RV uptake was encountered in 11 of the 118 patients, 
which is a similar proportion as that found in our study. Blankstein et al. also observed an elevated 
risk of VT and death in patients with abnormal RV uptake, regardless of whether they fulfilled the 
JMWH criteria for CS or not. In another study, which included 59 patients with systemic 
sarcoidosis, the proportion of patients with pathological RV uptake was 22%, and 85% of them 
fulfilled the JMWH criteria for CS (20).  
There are limitations related to this study. In some cases the conclusion was different between the 
two image interpreters. Cardiac FDG-PET has previously been shown to be difficult to interpret 
(21). In this study, a consensus was formed in cases where the interpretation differed between the 
readers. This is common practice when interpreting borderline studies in clinical situations. Because 
of the cross-sectional nature of this study, causality could not be assessed. Reflecting the ethnic 
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background of the majority of the Finnish population, our study group consisted of mainly white 
Caucasians; therefore, these results cannot be directly generalized in other populations. One major 
limitation concerning all studies investigating CS is the lack of accurate diagnostic gold standard. 
As the diagnosis of CS was biopsy-proven in only seven of the patients, one cannot be certain of the 
underlying cause of all abnormal PET findings. In the case of pathological PET findings, perfusion 
imaging might improve diagnostic accuracy (10). However, in our institution it is not routinely 
performed in combination with cardiac PET. Furthermore, this particular study dealt with PET only; 
perfusion imaging would not have changed the categorization of the findings. 
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Conclusion  
Abnormal LV-uptake and RV-uptake were associated with female sex and a history of advanced 
AV-block. Especially abnormal RV-uptake was predominantly encountered in female patients. 
Abnormal RV uptake was also associated with ventricular tachycardia and atrial fibrillation. One 
third of the patients with abnormal RV-uptake were later diagnosed with EMB-verified cardiac 
sarcoidosis. These results can be utilized in diagnostic work-up of cardiac sarcoidosis.  
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New Knowledge Gained 
Highest frequency  of pathological cardiac PET-findings was encountered in female patients with 
history of both advanced AV-block and VT.   
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Table 1. Baseline variables in patients with pathological or normal left ventricle FDG-
PET-finding. 
 
Variable 
Abnormal LV-uptake 
(n =33) 
Normal LV-uptake 
(n=104) 
p 
Gender, female/male  20/13 (61/39%) 37/67 (36/64%) 0.002* 
Age, years  45.8 ±12.1 43.7 ±13.2 0.401 
Body mass index 26.2 ±3.9 28.3 ±5.9 0.053 
History of:  
     II or III degree AV-block 23 (70%) 
 
33 (32%) 
 
<0.001 
     Ventricular tachycardia 23 (70%) 52 (50%) 0.053 
     Atrial fibrillation 16 (49%) 37 (36%) 0.185 
     Heart failure 14 (42%) 53 (51%) 0.393 
     Pulmonary sarcoidosis 10 (30%) 17 (16%) 0.208 
     Any heart disease 22 (67%) 64 (62%) 0.595 
Reasons for referral:    
     AV-block 25 (76%) 35 (34%) <0.001* 
     Supraventricular arrhythmia 3 (9%) 10 (10%) 0.541 
     Ventricular arrhythmia 5 (15%) 34 (33%) 0.052 
     Dilated cardiomyopathy 6 (18%) 22 (21%) 0.712 
     Abnormal echo findings 14 (43%) 39 (38%) 0.613 
     Syncope 6 (18%)  22 (21%) 0.712 
CS-positive EMB (n=21) 6 (18%) 1 (1%) 0.190 
 
 
Figures are n (%) for dichotomous and mean (+/- SD) for continuous variables.  
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Abbreviations: CS=cardiac sarcoidosis; EMB=endomyocardial biopsy; FDG-PET= 
¹⁸Fluorodeoxyglucose positron emission tomography; LV= left ventricle; AV=atrio-ventricular 
 
Table 2. Baseline variables in patients with or without pathological right ventricular 
FDG-PET-finding. 
 
Variable 
Abnormal RV-uptake 
(n =12) 
Normal RV-uptake 
(n=125) 
p 
Gender, female/male  10/2 (83/17%) 49/76 (39/61%) 0.004* 
Age, years  44.7 ±8.2 44.1 ±13.3 0.878 
Body mass index 28.0 ±5.7 25.8 ±4.1 0.188 
History of:  
     II or III degree AV-block 9 (75%) 
 
47 (37%) 
 
0.014* 
     Ventricular tachycardia 11 (92%) 64 (52%) 0.006* 
     Atrial fibrillation 8 (67%) 45 (36%) 0.040* 
     Heart failure 5 (42%) 62 (50%) 0.413 
     Pulmonary sarcoidosis 4 (33%) 23 (18%) 0.249 
     Any heart disease 10 (83%) 76 (61%) 0.106 
Reasons for referral:    
     AV-block 10 (83%) 50 (40%) 0.004* 
     Supraventricular arrhythmia 1 (8%) 12 (10%) 0.682 
     Ventricular arrhythmia 4 (33%) 35 (28%) 0.461 
     Dilated cardiomyopathy 1 (8%) 27 (22%) 0.250 
     Abnormal echo findings 5 (43%) 48 (38%) 0.527 
     Syncope 4 (33%) 24 (19%) 0.209 
CS-positive EMB (n=21) 4 (33%) 3 (2%) 0.537 
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Figures are n (%) for dichotomous and mean (+/- SD) for continuous variables.  
Abbreviations: CS=cardiac sarcoidosis; EMB=endomyocardial biopsy; FDG-PET= 
¹⁸Fluorodeoxyglucose positron emission tomography; RV= right ventricle; AV=atrio-ventricular  
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Figure 1. Abnormal FDG uptake in left ventricular (A) and right ventricular (B) wall in 
different groups. 
 
 
 
 
 
 
 
 
